Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. - Wikidata - wikimedia - TriplyDB

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.

http://www.wikidata.org/entity/Q38290415

about

Exploiting tumor epigenetics to improve oncolytic virotherapy Targeted therapies in sarcomas: challenging the challenge Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics What Do We Know about the Role of miRNAs in Pediatric Sarcoma?Advances in sarcoma diagnostics and treatment Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma Melanoma-associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survival SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2.Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.The SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: relationship with extracellular matrix remodeling.Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells Epigenetic Regulators: New Therapeutic Targets for Soft Tissue Sarcoma.Clinical efficacy of vorinostat in a patient with leiomyosarcoma.Molecular marks for epigenetic identification of developmental and cancer stem cells Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma.Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluation Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay.Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis.A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression.Newer medical therapies for metastatic soft tissue sarcoma.SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.Therapeutic applications of histone deacetylase inhibitors in sarcoma.

P2860

Q21131237-4F41A130-8821-477E-A3B1-649E1E3B8A8B Q21285014-4198DDA0-E811-46A5-9649-2C33A7BA3177 Q24308344-810C1F89-B4B7-4385-835A-468F7599AA88 Q26800124-1B190174-11CC-4FC2-9833-2E7A6CBFCC37 Q28069695-4FB2B9A7-B5AF-432C-89C9-4AC0CA8E6695 Q28087134-E151266C-67C3-45EC-A4BB-5C0722C2E699 Q28468451-607D7436-2FAD-4DFC-BFCA-FF8280E3CC8F Q28483943-E9BE1C47-6E32-43F9-9718-C0DCF3B2DC55 Q28550973-078A51F3-1389-42E3-926A-A894718A9FF7 Q30914150-3246F65A-3B76-49B3-AD6B-C8DFC1A17802 Q33409579-1516162A-E840-4C4E-B8F0-85F53A9D8009 Q33419472-DBA4EB8D-1A00-4E1D-B67B-4E369393C8E3 Q33425217-5EDFEBD3-4643-432D-80E9-531FC4A65A93 Q33742171-1521DDF3-0DD0-4263-A724-089BD4639D6E Q33910609-DA731F7C-2C8F-47F8-931F-EC051FE5C0A3 Q34200411-797E585D-870A-47CD-A0B8-F22BBF25CC98 Q34272305-29C191F9-B808-4381-905C-A5740CA5F17E Q34621838-1AB30380-999E-4567-B9DC-D8B0A46D93EE Q34657445-1B6F6825-9A2D-4955-8348-BFFC0CB1968E Q35018901-2ADFE2DE-EB94-4D28-95D5-A0A9C62F8DB2 Q35117949-7B8B7047-9C2C-465F-86F9-811936366BA9 Q35734256-C26C4295-25DF-4F03-BF56-4056544047DD Q35789686-10F41A4F-7093-4A47-AB92-E5A509A8D1AF Q36001860-B1186FC1-79C6-43DC-9F4F-ADA97EBB8581 Q36071514-41054194-D04A-4D5A-B434-313060B7D8B0 Q36388149-5898DF0B-163C-4125-9E09-B2FA43A3B7E6 Q36548712-889488C2-4A5E-43FE-9582-AA151F799A3F Q36850467-9074AF52-5087-4EEE-A957-7E2D93AEA0BB Q37138320-8DE427AA-8547-4BC3-A05F-3DFB09D09157 Q37222595-C34DDB37-3E2B-4973-A70E-F71151BE64A7 Q37376281-11863BBB-72D9-4D53-B48B-5810DCF20C8D Q37468623-5F04AD00-C6AB-43D6-B0BB-B25432AD5AED Q37737327-3F628052-F4B6-4A80-9450-9467334DF5C8 Q37962606-7589F17B-151F-41FB-B48A-DA2AFC30D6A6 Q38336253-DFB089E3-8CFD-4794-BD1E-62108204A299 Q38567366-B805DD05-6CDB-4EF3-B863-4948D0484D86 Q38953852-8A7EE6AD-DE2E-46D0-A7D8-D4D548154AF4 Q39012067-10426B6A-AEB4-462D-8CE0-83B0C17B9EE7 Q39069350-9455FB40-F658-4305-B94B-0E5DA22A285A Q39450827-58B4EDC1-BC6F-4F4F-B6C0-152C4D0C65D3

P2860

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.

http://www.wikidata.org/entity/Q38290415

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Histone deacetylase inhibitors ...... esponse 1 in synovial sarcoma.

@en

type

label

Histone deacetylase inhibitors ...... esponse 1 in synovial sarcoma.

@en

prefLabel

Histone deacetylase inhibitors ...... esponse 1 in synovial sarcoma.

@en

P1433

Q38290415-21155672-2752-46A3-A35B-854BF433BCC0

P1476

Q38290415-B32F811D-9D7D-4FD4-9DC6-B881C2281AD2

P2093

Q38290415-0476A3F7-632E-4D56-BD16-0240C430EBC0

Q38290415-5A7E640C-34DF-4803-AA6F-1CF638197D48

Q38290415-6E424D14-0175-4500-B4EA-C7DFCAACFF93

Q38290415-7D66E3EC-0EC2-4CA2-8B6D-BD1AFC6F6820

Q38290415-837F3C88-0D48-4B63-BCB0-41209DD7A283

Q38290415-8AF734C2-3673-4BFC-AF19-72FBFC18DEA2

Q38290415-BFE41DC7-E2FD-4FB8-B926-EBF7812D7AB0

P304

Q38290415-65013182-B24C-43E8-9F25-9381648E8668

P31

Q38290415-310B934F-0A7D-49FB-A09F-0A27E43EF872

P356

Q38290415-637D4913-571E-41EC-91D6-67C5D176E751

P407

Q38290415-9B7DB999-F960-4D03-B072-47B951E79422

P433

Q38290415-4CC0FEC9-0BA2-46D2-9D84-D059C7FBC730

P478

Q38290415-2A351523-7841-4691-9CBC-103F8E6D636E

P50

Q38290415-2DA4AF78-EC37-4BCB-930C-E054409552D1

Q38290415-58A8FB78-551C-425D-98E6-2D98A968FB3E

Q38290415-920332DC-2F4F-4C9D-B962-F61E23198DAC

P577

Q38290415-48B41BBA-7B39-44AE-A623-81EEA257B83D

P698

Q38290415-DBF55ABC-90F2-4BE5-BA72-0B021FEA5EDC

P356

0008-5472.CAN-08-0092

P1433

Cancer Research

P1476

Histone deacetylase inhibitors ...... esponse 1 in synovial sarcoma.

@en

P2093

Ad Geurts van Kessel

http://www.w3.org/2001/XMLSchema#string

Anke H A van Dijk

http://www.w3.org/2001/XMLSchema#string

Diederik R H de Bruijn

http://www.w3.org/2001/XMLSchema#string

Joanna M Lubieniecka

http://www.w3.org/2001/XMLSchema#string

Le Su

http://www.w3.org/2001/XMLSchema#string

Neal Poulin

http://www.w3.org/2001/XMLSchema#string

Torsten O Nielsen

http://www.w3.org/2001/XMLSchema#string

P304

4303-4310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-0092

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Adrianus Henricus Maria Geurts van Kessel

Subbaya Subramanian

Matt van de Rijn

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18519690

http://www.w3.org/2001/XMLSchema#string